Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ductal adenocarcinoma.

BMC Cancer · 2025 · PMC12093888 · PMID 40394523

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

We saw a clear trend towards higher concentrations of cβigH3 for degraded matrices generated with TGF-β treatment (mean = 11.7 nM) compared to matrices generated without TGF-β treatment (mean = 4.3 nM) (Fig. 2 ), indicating that cβigH3 is associated with degradation of fibrotic matrices. cβigH3 could be detected in serum from patients with different types of cancer We measured cβigH3 in serum from cohort 1.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.